| Previous Section | Index | Home Page |
6 Nov 2003 : Column 784W—continued
Health Care (York)
Hugh Bayley: To ask the Secretary of State for Health what NHS expenditure (a) in cash terms and (b) at current prices on services provided by GP surgeries, other than NHS prescription items, was in York in each year since 1992. [135958]
Miss Melanie Johnson: Information for York is not available. The table shows information for the nearest geographical match to York.
Sources:
1. North Yorkshire Family Health Services Authority audited annual accounts 1992–93 to 1995–96.
2. North Yorkshire Health Authority audited annual accounts 1996–97 to 1998–99.
3. North Yorkshire Health Authority audited summarisation forms 1999–2000 to 2001–02.
4. Selby and York Primary Care Trust audited summarisation schedules 2001–02.
5. HM Treasury GDP Deflator.
6 Nov 2003 : Column 785W
Hugh Bayley: To ask the Secretary of State for Health what capital investment (a) in cash terms and (b) at current prices has been at York District Hospital in each year since 1992. [135962]
Miss Melanie Johnson: The requested information is shown in the table.
| Cash terms | Current prices | |
|---|---|---|
| 1992–93 | 5,791 | 7,436 |
| 1993–94 | 6,028 | 7,507 |
| 1994–95 | 7,456 | 9,184 |
| 1995–96 | 8,841 | 10,545 |
| 1996–97 | 2,708 | 3,135 |
| 1997–98 | 1,457 | 1,636 |
| 1998–99 | 3,185 | 3,481 |
| 1999–2000 | 2,778 | 2,981 |
| 2000–01 | 6,571 | 6,931 |
| 2001–02 | 4,159 | 4,278 |
Source:
York Hospitals NHS Trust: Net Book Value of Purchased Capital Additions for each year.
Hugh Bayley: To ask the Secretary of State for Health how many nurses were in training at York nursing school in each year since 1992. [136050]
Miss Melanie Johnson: The information requested is shown in the table.
| At 1 April | Number |
|---|---|
| 1992(4) | 357 |
| 1993(4) | 319 |
| 1994 | 554 |
| 1995 | 488 |
| 1996 | 380 |
| 1997 | 397 |
| 1998 | 425 |
| 1999 | 491 |
| 2000 | 544 |
| 2001 | 596 |
| 2002 | 638 |
| 2003 | 637 |
(4) Figures for 1992 and 1993 relate to York and Scarborough College of Nursing only, as Harrogate and Northallerton School of Nursing was a separate institution at this time.
Source:
University of York.
6 Nov 2003 : Column 786W
Hugh Bayley: To ask the Secretary of State for Health what progress has been made with implementing the National Service Framework for Older People in York. [136052]
Miss Melanie Johnson: Selby and York Primary Care Trust (PCT) submitted a report on progress towards the milestones set out in the national service framework to its older people's partnership board in September 2003. This report shows the work which has been done to bring about improvements for older people, to work in partnership across organisational boundaries and to ensure a sharp focus on the development of services that are person/patient-centred, joined-up, timely and active in promoting health in older age. A full copy of the report is available from Selby and York PCT.
Hugh Bayley: To ask the Secretary of State for Health when digital hearing aids will be offered to NHS patients in York. [136053]
Miss Melanie Johnson: York Hospitals National Health Service Trust will begin fitting digital hearing aids as part of the modernised hearing aid service by March 2004.
Health Services (North-West)
Mr. Evans: To ask the Secretary of State for Health how much has been spent in the NHS in the North West since 1992. [134893]
Miss Melanie Johnson: Expenditure in the area covered by the former North West Regional Office and the North West Regional Health Authority areas since 1992–93 is shown in the table.
| £ million | |
|---|---|
| 1992–93 | 3,848 |
| 1993–94 | 4,047 |
| 1994–95 | 4,383 |
| 1995–96 | 4,564 |
| 1996–97 | 4,427 |
| 1997–98 | 4,290 |
| 1998–99 | 4,712 |
| 1999–2000 | 5,497 |
| 2000–01 | 5,996 |
| 2001–02 | 6,348 |
| 2002–03 | 7,510 |
| Total | 55,622 |
Notes:
1. The figures are based on the North West Regional Office area as in 2001–02, taking into consideration boundary changes over the period.
2. Figures do not include NHS expenditure, which is not accounted for by the health authorities, eg General Dental Services.
3. Figures are not consistent between years as there have been considerable changes in the types of expenditure accounted for by health authorities in different years, eg prescribing expenditure.
4. All figures are cash based.
Sources:
1992–93 to 1995–96 audited accounts of Family Health Services Authorities
1992–93 to 1995–96 audited accounts of District and Regional Health Authorities
1996–97 to 1998–99 audited accounts of Health Authorities
1999–2000 to 2001–02 audited summarisation forms of Health Authorities
2002–03 audited summarisation forms of Strategic Health Authorities
2000–01 to 2002–03 audited summarisation schedules of Primary Care Trusts
6 Nov 2003 : Column 787W
Mental Health
Mrs. Calton: To ask the Secretary of State for Health what assessment he has made of the long-term savings to the NHS that might be achieved by the provision of free prescriptions for people with long-term mental health problems. [135963]
Ms Rosie Winterton: The Department has not made an assessment of the long-term savings to the national health service of providing free prescriptions for people with mental health problems.
Our policy is to help those who may have difficulty in paying prescription charges, rather than extending the exemption arrangements. By using a prescription prepayment certificate, no one need pay more than £32.90 for four months or £90.40 for 12 months, for all the NHS medication that they are prescribed.
Nurses
Mr. Rooney: To ask the Secretary of State for Health what provisions in the Statutory Instrument on Nurses, Midwives and Health Visitors Rules Approval, SI No. 873, 1983, are still in force. [136164]
Mr. Hutton [holding answer 4 November 2003]: The provisions made in these rules (now operated by the Nursing and Midwifery Council) remain effective. These remain in force by virtue of schedule 2 of the Nursing and Midwifery Order 2001 (S.I. 2002/253).
Paediatric Services
Mr. Boswell: To ask the Secretary of State for Health what action he is taking to ensure that drug treatments currently licensed for adults are evaluated and made available for paediatric use. [134495]
Miss Melanie Johnson: The current legislative framework governing the authorisation of medicinal products contains neither obligations nor incentives to either evaluate medicinal products for use in the paediatric population or to make the products available for paediatric use. The United Kingdom is taking an active part in developing European legislation which will establish a system of obligations and incentives for the development and evaluation of medicines for paediatrics use. This is, however, unlikely to be finalised before 2006.
In the meantime, the UK will continue to use the existing regulatory framework to encourage the pharmaceutical industry to evaluate medicines for use in the paediatric population. The Committee on Safety of Medicines, an independent expert committee that advises the Licensing Authority has established a paediatric sub-group to provide expert advice on the regulatory strategy to improve the availability of medicines licensed for use in children.
6 Nov 2003 : Column 788W
The Medicines and Healthcare products Regulatory Agency (MHRA) routinely asks companies for paediatric development plans where appropriate, both pre- and post-licensing. In addition, when a marketing authorisation for a medicinal product is granted or amended the pharmaceutical companies are required by the Licensing Authority to provide evidence-based statements on paediatric use in the summary of product characteristics. The MHRA monitors authorisations granted for the paediatric use of medicines in the United States and contacts the marketing authorisation holder with a request for the data to be submitted to the MHRA for assessment. Several companies have submitted data in response to such requests and UK authorisations for paediatric use have been granted as a result. In other cases, the MHRA has asked companies to consider developing formulations of medicinal products that are specifically adapted for paediatric use. Following positive responses, the MHRA is actively discussing formulation development plans with several companies.
The MHRA is keeping the UK pharmaceutical industry informed of legislative developments at the European level and has offered to give regulatory and scientific advice on the development of medicines for paediatric use.
| Next Section | Index | Home Page |